89ZR-BEVACIZUMAB ( DrugBank: Bevacizumab, 89ZR-BEVACIZUMAB )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 34 | 神経線維腫症 | 1 |
34. 神経線維腫症
臨床試験数 : 137 / 薬物数 : 213 - (DrugBank : 76) / 標的遺伝子数 : 87 - 標的パスウェイ数 : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000156-35-NL (EUCTR) | 18/03/2021 | 03/03/2020 | 89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2. | 89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2. - 89Zr-Bevacizumab PET/CT imaging in NF2 patients | Neurofibromatosis type 2;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: 89Zr-bevacizumab INN or Proposed INN: Unknown Other descriptive name: BEVACIZUMAB ZIRCONIUM ZR-89 | Leiden University Medical Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 15 | Phase 2 | Netherlands |